Thrombolytic therapy plays a vital role in reperfusion strategy for ST-segment elevation myocardial infarction(STEMI)patients.Previous Chinese expert consensus focused on pre-hospital thrombolysis therapy in STEMI patients was published in 2018 which tremendously promoted pre-hospital thrombolysis therapy.In recent years,plenty of research progress and results of clinical trials have been released in following areas such as STEMI reperfusion strategy,anti-platelet/anti-coagulants therapy,contemporary facilitated percutaneous coronary intervention,and so on.Meanwhile,the COVID-19 pandemic makes timely reperfusion for STEMI patients even more challenging.Therefore,this consensus has been proposed aiming to summarize recent progress in STEMI thrombolysis therapy and to provide practical & evidence-based instructions conforming to national conditions.We hope this consensus will contribute to the emergency management and long-term prognosis of STEMI patients.

Transcatheter aortic valve replacement(TAVR)has reached maturity and has entered a stage of steady and stable development in China.From 2017 to 2023,the number of centers conducting TAVR in China has increased from less than 10 to over 600,and the annual implantation volume has increased from hundreds to over 10 000.The 2018 and 2021 editions of the"Expert Consensus on Clinical Pathway for Transcatheter Aortic Valve Replacement in China"played a crucial guiding role during the golden period of TAVR development in China.With significant progress in evidence-based practice,clinical experience,guideline updates,device development,and procedure technique improvements in the TAVR field,especially the important advances in technologies developed from China,protocol optimization based on Chinese clinical practices,it is necessary to update the previous clinical pathway consensus.The new version of the clinical pathway expert consensus has updated the standard procedures for preoperative clinical assessment,perioperative imaging evaluation,standardized procedural processes,comprehensive perioperative management,and postoperative rehabilitation follow-up for TAVR patients.This update aims to further promote the healthy and standardized development of TAVR technology in China and to steadily enhance the medical and scientific research capabilities with this therapeutic technology.

Chinese expert consensus on neurosurgical treatment of psychiatric disorders is compiled by national experts in neurosurgery,psychiatry,and other related fields.Based on clinical research published up to December 2023 and evidence-based medicine standards,the consensus provides recommendations for neurosurgical treatment of psychiatric disorders.The covered diseases include obsessive-compulsive disorder,depressive disorder,tic disorder,bipolar disorder,anorexia nervosa,substance use-related disorders,and schizophrenia.This expert consensus outlines the safety and efficacy of neurosurgical treatments for psychiatric disorders in clinical practice,and preliminarily standardizes treatment procedures and surgical techniques.The aim is to establish professional standards for the application of surgical treatment techniques for clinical practitioners in the field of psychiatric disorder surgery,thereby maximizing treatment outcomes and promoting the future development of this treatment technology.

As cardiovascular disease(CVD)incidence and mortality rates continue to rise in China,the importance of identifying and managing CVD risk factors grows.Obstructive sleep apnea(OSA)is a prevalent sleep-related breathing disorder,affecting an estimated 936 million individuals aged 30-69 worldwide,with China leading globally with 176 million affected.Increasing research indicates a close association between OSA and the onset and progression of various CVD,significantly affecting outcomes.However,OSA has long been underrecognized and undertreated in CVD clinical practice.To address this,National Expert Commission for Cardiovascular Diseases,Cardiovascular Group,Chinese Academy Society of Sleep Medicine,Chinese Medical Doctor Association,and Geriatric Sleep Disorders and Cardiopulmonary Group,Division of Sleep Science and Technology,China Association of Gerontology and Geriatrics convened multidisplinary experts to formulate the"Expert Consensus on the Evaluation and Management of Obstructive Sleep Apnea in Patients With Cardiovascular Diseases(2024 Edition)".This consensus addresses core clinical issues such as screening,diagnosis,treatment,and follow-up of CVD patients with OSA.It offers 17 recommendations on common clinical questions,based on current evidence-based medicine,following extensive discussions and votes,aiming to standardize the assessment and management of OSA in Chinese CVD patients,support clinical decision-making,and improve clinical care and service quality.

Effective lipid management can significantly reduce the burden of atherosclerotic cardiovascular disease(ASCVD).However,lipid management for ASCVD prevention and treatment in China still faces the challenges of low attainment rate and poor adherence.An increasing body of evidence suggests that a single-pill combination(SPC)of statin and non-statin agents is effective for improving blood lipid control rate,improving treatment adherence,and reducing adverse cardiovascular events.To standardize the clinical application of the cholesterol-lowering single-pill combination therapy in China,the"Chinese Expert Consensus on Clinical Application of Single-pill Combination of Cholesterol-lowering Agents"was developed with the efforts of a number of domestic experts from cardiovascular,cerebrovascular,endocrinological,and pharmacological fields.The advantages in clinical application and clinical research of cholesterol-lowering SPC were elaborated in this consensus,and the clinical pathway of lipid management for ASCVD prevention and treatment was formulated.Meanwhile,suggestions on the applicable population,usage and dosage,and management of adverse events of cholesterol-lowering SPC were provided.

Transcatheter aortic valve replacement (TAVR) has reached maturity and has entered a stage of steady and stable development in China.From 2017 to 2023,the number of centers conducting TAVR in China has increased from less than 10 to over 600,and the annual implantation volume has increased from hundreds to over 10000.The 2018 and 2021 editions of the "Expert Consensus on Clinical Pathway for Transcatheter Aortic Valve Replacement in China" played a crucial guiding role during the golden period of TAVR development in China.With significant progress in evidence-based practice,clinical experience,guideline updates,device development,and procedure technique improvements in the TAVR field,especially the important advances in technologies developed from China,protocol optimization based on Chinese clinical practices,it is necessary to update the previous clinical pathway consensus.The new version of the clinical pathway expert consensus has updated the standard procedures for preoperative clinical assessment,perioperative imaging evaluation,standardized procedural processes,comprehensive perioperative management,and postoperative rehabilitation follow-up for TAVR patients.This update aims to further promote the healthy and standardized development of TAVR technology in China and to steadily enhance the medical and scientific research capabilities with this therapeutic technology.

Providing adequate and balanced nutrition for preterm infants,especially extremely/very preterm infants,is the material basis for promoting their normal growth and development and improving long-term prognosis.Enteral nutrition is the best way to feed preterm infants.Previous systematic reviews have shown that using evidence-based standardized feeding management strategies can effectively promote the establishment of full enteral feeding,reduce the duration of parenteral nutrition,improve the nutritional outcomes of preterm infants,and not increase the risk of necrotizing enterocolitis or death.Based on relevant research in China and overseas,the consensus working group has developed 20 recommendations in 5 aspects including the goal of enteral nutrition,transitioning to enteral nutrition,stable growth period enteral nutrition,supplementation of special nutrients,and monitoring of enteral nutrition for preterm infants,using the Grading of Recommendations Assessment,Development and Evaluation.The aim is to provide recommendations for healthcare professionals involved in the management of enteral nutrition for preterm infants,in order to improve the clinical outcomes of preterm infants.

Establishing enteral nutrition after the birth of preterm infants presents numerous challenges,particularly for those in special situations.Various disease factors and medical interventions impede the establishment of enteral feeding,leading to conflicts and controversies regarding feeding goals,feeding methods,and the challenges and solutions faced by these infants.A critical issue for clinical physicians is how to safely and promptly establish enteral nutrition to achieve full enteral feeding as quickly as possible.The consensus formulation working group,based on both domestic and overseas research,adopted the Grading of Recommendations Assessment,Development and Evaluation,and formed an expert consensus on enteral nutrition management for preterm infants in special situations.This consensus provides 14 recommendations for 9 common special situations,aiming to offer guidance on enteral nutrition management for preterm infants to improve their short and long-term outcomes.

Chronic hepatitis B(CHB)is still a major public health issue in China,and without effective control,it can further progress to liver cirrhosis and liver cancer,bringing huge social and economic burdens.At present,antiviral therapy is the main treatment method for CHB,and integrated traditional Chinese and Western medicine therapy is the characteristic treatment method for CHB in China and can improve clinical efficacy by complementing each other's advantages.In order to promote the concept integrated traditional Chinese and Western medicine collaborative diagnosis and treatment,facilitate the development of integrated traditional Chinese and Western medicine diagnosis and treatment techniques for CHB,and establish standardized disease diagnosis and treatment regimens,Expert Committee on Hepatology in Doctor Society of Integrative Medicine,Chinese Medical Doctor Association,established a consensus expert group to discuss and formulate Expert consensus on integrated traditional Chinese and Western medicine diagnosis and treatment of chronic hepatitis B,which elaborated on the concept of integrated traditional Chinese and Western medicine collaborative diagnosis and treatment from the four aspects of CHB epidemiology,pathogenesis and etiology,integrated traditional Chinese and Western medicine diagnosis and syndrome differentiation,and integrated traditional Chinese and Western medicine therapy and proposed related recommendations,in order to improve the prognosis and quality of life of CHB patients.

Autoimmune pancreatitis(AIP)is an immune-mediated,special type of chronic pancreatitis,which can involve multiple organs.The clinical manifestation of AIP is complex and varied,making the diagnosis and treatment challenging.With reference to the latest guidelines and studies from both domestic and international sources,this guideline comprises 20 recommendations regarding the diagnosis,treatment,follow-up,and prognosis of AIP.The aim of this guideline is to promote the care capability and improve the outcome of patients with AIP in China.